S

    Soligenix Inc. (SNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.38
    +0.00 (+0.85%)

    Market Cap: $8.20M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    -6.92%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.09+0.0%
    60d ago$-0.09+0.0%
    30d ago$-0.09+0.0%
    7d ago$-0.09+0.0%
    Current$-0.09
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$0.02
    Range$0.02 - $0.02
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.09---
    Jun 26
    		$-0.12$-0.22+45.45%Beat+85.4%
    Mar 26
    		$-0.28$-0.30+6.67%Beat+73.6%
    Dec 25
    		$N/A$-0.27N/ABeat-
    Sep 25
    		$-0.58$-0.48-20.83%Miss+25.6%
    Jun 25
    		$-0.82$-1.05+21.90%Beat+37.4%
    Mar 25
    		$-1.06$-0.67-58.21%Miss-488.9%
    Dec 24
    		$-1.14$-1.56+26.92%Beat+55.5%
    Sep 24
    		$-0.78N/A+53.85%Beat+69.5%
    Jun 24
    		$-1.31$-1.77+25.99%Beat+62.8%
    Mar 24
    		$-0.18$-0.19+5.26%Beat+96.9%
    Dec 23
    		$-2.56$-3.12+17.95%Beat+44.1%
    Sep 23
    		$-2.56$-4.64+44.83%Beat+86.7%
    Jun 23
    		$-3.52$-6.08+42.11%Beat+74.1%
    Mar 23
    		$-5.76N/A+71.20%Beat+76.6%
    Dec 22
    		$-4.58$-1.12-308.93%Miss-177.6%
    Sep 22
    		$-19.20$-21.60+11.11%Beat+8.6%
    Jun 22
    		$-13.58$-24.00+43.42%Beat-13.2%
    Mar 22
    		$-24.62$-19.20-28.23%Miss-54.3%
    Dec 21
    		$-1.65$-1.20-37.50%Miss+31.3%
    Sep 21
    		$-21.00$-19.20-9.38%Miss-42.8%
    Jun 21
    		$-12.00N/A+54.55%Beat+52.2%
    Mar 21
    		$-15.96$-16.80+5.00%Beat+40.5%
    Dec 20
    		$-2.40$-1.20-100.00%Miss-14.3%
    Sep 20
    		$-14.71N/A+56.22%Beat+56.2%
    Jun 20
    		$-25.08$-38.40+34.69%Beat+12.9%
    Mar 20
    		$-26.81$-36.00+25.53%Beat-24.1%
    Dec 19
    		$-2.10$-1.99-5.53%Miss+22.2%
    Sep 19
    		$-33.60$-33.60+0.00%Beat-27.3%
    Jun 19
    		$-28.80$-33.60+14.29%Beat+33.3%
    Mar 19
    		$-21.60$40.80-152.94%Miss-7900.0%
    Dec 18
    		$-2.70$-2.25-20.00%Miss+95.8%
    Sep 18
    		$-26.40$-24.00-10.00%Miss+35.3%
    Jun 18
    		$-43.20$-48.00+10.00%Beat+56.1%
    Mar 18
    		$-0.27$-0.25-8.00%Miss+94.4%
    Dec 17
    		$-64.80$-69.60+6.90%Beat+88.5%
    Sep 17
    		$-40.80N/A+54.05%Beat+61.0%
    Jun 17
    		$-98.40$-77.60-26.80%Miss-
    Mar 17
    		$-4.80$-6.75+28.89%Beat-
    Dec 16
    		$-563.47$-165.60-240.26%Miss-
    Sep 16
    		$-104.69$-208.80+49.86%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.21EV/EBITDA-0.12x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-241.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage184.08x
    Current Ratio2.77xQuick Ratio2.77x
    Trading Statistics
    Beta1.92Avg Volume247.16K
    52-Week High$3.2252-Week Low$0.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.39
    SMA 20$0.39
    SMA 50$0.38
    SMA 200$0.91
    EMA 10$0.39
    EMA 20$0.39
    EMA 50$0.42
    EMA 200$0.87

    MACD

    Line: -0.00Signal: -0.00Hist: -0.00

    ADX

    ADX: 21.0+DI: 18.8-DI: 19.5

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down8.0
    PSAR$0.42

    Bollinger Bands

    Upper Band$0.41
    Lower Band$0.37
    %B Position995%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    47.0

    Momentum Oscillators

    Stoch %K16.1
    Stoch %D18.3
    Williams %R-66.5
    ROC (10d)-0.3%
    Momentum-0.00
    CCI (20d)-123.2
    MFI (14d)56.3

    Volatility Measures

    ATR (14d)$0.02(5.4%)
    StdDev (20d)0.01
    Hist Vol48.7%(High)

    Volume Flow

    VWAP$0.38
    OBV942.3M
    AD Line-316.6M
    CMF (20d)-0.206

    Volume Metrics

    Avg Vol (20d)249.6K
    Vol Ratio1.6x(High)
    VWMA (20d)$0.39

    Pivot Points

    R3$0.40
    R2$0.40
    R1$0.39
    Pivot Point$0.38
    S1$0.37
    S2$0.37
    S3$0.36

    Advanced Oscillators

    TSI-0.89
    Ultimate Osc41.9
    KST41.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$6,352$0$2,342$117,029$244,812$130,440
    Cost of Revenue$0$0$1,000$0$0$0$3,175$0$2,342$117,029$221,546$110,441
    Gross Profit$0$0$-1,000$0$0$0$3,176$0$0$0$23,266$19,999
    Operating Expenses$2.10M$2.88M$3.19M$2.58M$2.76M$3.03M$3.71M$1.87M$1.74M$2.12M$2.16M$1.80M
    R&D$974,091$1.78M$2.00M$1.58M$1.68M$1.94M$2.66M$968,689$501,158$1.10M$777,534$826,015
    SG&A$1.13M$1.10M$1.19M$996,604$1.09M$1.08M$1.05M$896,547$1.24M$1.02M$1.38M$973,040
    Operating Income$-2,099,463$-2,884,838$-3,189,111$-2,580,483$-2,763,879$-3,026,508$-3,712,495$-1,865,236$-1,744,675$-2,117,091$-2,137,871$-1,779,056
    Interest Income$53,598$61,389$71,968$52,351$69,823$76,028$70,372$78,836$35,925$28,842$48,270$66,363
    Interest Expense$-58,443$0$0$0$0$0$0$0$0$0$288,630$0
    Income Before Tax$-1,987,354$-2,824,965$-3,117,309$-2,530,947$-2,701,976$-2,951,268$-3,396,480$-1,719,381$-1,644,502$-1,915,327$-2,426,501$-1,662,702
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$-606,606$0
    Net Income$-1,987,354$-2,824,965$-2,610,694$-2,530,947$-2,701,976$-2,951,268$-2,987,366$-1,719,381$-1,644,502$-1,915,327$-1,819,895$-1,662,702
    EBITDA$-2,098,298$-2,885,256$-3,188,275$-2,582,387$-2,771,096$-3,026,688$-3,465,803$-1,796,628$-1,678,839$-1,942,581$-2,473,181$-1,727,476
    EBIT$-2,099,395$-2,886,354$-3,189,277$-2,583,298$-2,771,799$-3,027,296$-3,466,852$-1,798,217$-1,680,427$-1,944,169$-2,474,771$-1,729,065
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SNGX

    News

    Soligenix Inc (SNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Soligenix Inc (SNGX), highlighting its current earnings forecast score of 8.00 and an average price target of $17.50 from one analyst. The analyst suggests a "Buy" trend for the stock, with a forecasted EPS of USD -0.10 for the next quarter. The article also notes the company's recent EPS performance and compares its analyst ratings to peers in the Biotechnology & Medical Research industry.

    TradingKey•8/14/26•
    Bullish

    SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

    Soligenix, Inc. (NASDAQ: SNGX) is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a vaccine against the Bundibugyo virus, in collaboration with Dr. Axel Lehrer. The application will leverage previous work on bivalent and trivalent thermostable vaccines for filoviruses using Soligenix's ThermoVax® platform. This platform offers the advantage of extended stability, crucial for vaccine distribution in regions lacking cold-chain infrastructure.

    Yahoo Finance•8/12/26•
    Somewhat-Bullish

    Soligenix culls topical lymphoma asset after Phase III miss

    Soligenix has ended the development of its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte, after the drug failed to meet its primary goals in a Phase III trial. The company will now focus on its pipeline candidate, dusquetide, for Behçet's disease and developing commercial opportunities for its ThermoVax platform for vaccines. This decision follows an interim analysis of the FLASH2 trial which indicated the treatment was unlikely to succeed.

    Yahoo Finance•8/10/26•
    Bearish

    Soligenix (SNGX) Receives a Buy from Alliance Global Partners

    Alliance Global Partners analyst James Molloy maintained a Buy rating on Soligenix (SNGX) with a price target of $1.50. Despite Molloy's historical average return, the analyst consensus on Soligenix is a Moderate Buy with an average price target of $1.50. The company recently reported a quarterly GAAP net loss of $2.82 million, an improvement from the previous year.

    The Globe and Mail•8/9/26•
    Bullish

    Soligenix Releases Q2 2026 Financial Results

    Soligenix, Inc. reported a Q2 2026 loss per share of $0.12 and a net loss of $2.0M, representing an 85.4% improvement from the previous year. This progress in narrowing its operating deficit, coupled with positive analyst outlooks, reflects growing confidence in the biopharmaceutical company's pipeline for rare disease treatments. The company focuses on developing therapies for underserved patient populations and operates in a niche segment with high potential returns upon successful commercialization.

    AlphaStreet•8/8/26•
    Neutral

    Frequently Asked Questions About SNGX

    Does SNGX pay dividends?
    Soligenix Inc. (SNGX) does not currently pay a regular dividend.
    What is SNGX's market cap?
    Soligenix Inc. (SNGX) has a market capitalization of $8.20M with a current stock price of $0.38.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In